The Valley Desk

NCT06921785 · Interventional trial

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Overall registry status Recruiting

Phase 3

Conditions Hepatocellular Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov